Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909934 | 0.86 | NPC1 (0.41) | PTGER4MAPTF10ALDH1A1GRIN2B | |
| SCHEMBL6716 | 0.84 | ATM (0.39) | F10ALDH1A1FASN | |
| SCHEMBL11183 | 0.84 | SCD (0.44) | MAPT | |
| SCHEMBL6714 | 0.84 | ATM (0.39) | F10ALDH1A1FASN | |
| SCHEMBL10298 | 0.83 | F10 (0.41) | F10ALDH1A1FASNGRIN2B | |
| SCHEMBL11909767 | 0.83 | PTGER4 (0.45) | PTGER4LMNAMAPTIDO1TDO2 | |
| SCHEMBL2009115 | 0.80 | ELANE (0.46) | LMNAMAPTF10ALDH1A1FASN | |
| SCHEMBL2009118 | 0.80 | ELANE (0.46) | LMNAMAPTF10ALDH1A1FASN | |
| SCHEMBL10320 | 0.78 | IDO1 (0.38) | IDO1TDO2F10FASN | |
| SCHEMBL6065 | 0.75 | HTT (0.45) | LMNAMAPTF10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | PTGER4 2567/4885LMNA 3101/4885MAPT 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.